A Double-blind, Randomized Clinical Trial to Evaluate the Lot-to-lot Consistency, Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) Between Different Workshops for Prevention of COVID-19 in Healthy Children Aged 3-17 Years
Latest Information Update: 10 Nov 2023
At a glance
- Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Aluminium hydroxide
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors Sinovac Biotech
- 05 Nov 2023 Planned End Date changed from 25 Jun 2022 to 25 Dec 2023.
- 13 Dec 2021 Status changed from recruiting to active, no longer recruiting.
- 15 Nov 2021 New trial record